Uses
For mydriasis and cycloplegia for diagnostic procedures.
Source: US FDA prescribing information
- Presentations
- 3
- Brands
- 1
- Manufacturers
- 1
- Available from stock
- 0
Tropicamide is an anticholinergic. It is available as eye drops for ophthalmic use. MedsAcross supplies Tropicamide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Key facts
- Pharmacological class
- Anticholinergic, Cholinergic Antagonists
- ATC classification
- S01FA06 Tropicamide · Eye medicines, subgroup S01F, subgroup S01FA
- US FDA first approval
- 23 February 1960
- EU status
- Not recorded
- Orphan designation
- Not recorded
- WHO essential medicine
- Not recorded
- India (CDSCO)
- Not yet confirmed against CDSCO approval lists
- Routes
- Ophthalmic
- Dosage forms
- Eye drops
- Identifiers
- UNII N0A3Z5XTC6RxCUI 10869CAS 1508-75-4DrugBank DB00809Q29310
Clinical information
From the regulator-approved product information. Each section names its source.
Dosing overview
For refraction, instill one or two drops of 1% solution in the eye(s), repeated in five minutes. If patient is not seen within 20 to 30 minutes, an additional drop may be instilled to prolong mydriatic effect. Individuals with heavily pigmented irides may require higher strength or more doses. Mydriasis will reverse spontaneously with time, typically in 4 to 8 hours. However, in some cases, complete recovery may take up to 24 hours.
Source: US FDA prescribing information
Contraindications
Contraindicated in persons showing hypersensitivity to any component of this preparation.
Source: US FDA prescribing information
Warnings and precautions
FOR TOPICAL OPHTHALMIC USE ONLY. NOT FOR INJECTION. This preparation may cause CNS disturbances which may be dangerous in pediatric patients. The possibility of psychotic reactions and behavioral disturbances due to hypersensitivity to anticholinergic drugs should be considered. Mydriatics may produce a transient elevation of intraocular pressure. Remove contact lenses before using.
Source: US FDA prescribing information
Side effects
Ocular: Transient stinging, blurred vision, photophobia and superficial punctuate keratitis have been reported with the use of tropicamide. Increased intraocular pressure has been reported following the use of mydriatics. Non-Ocular: Dryness of the mouth, tachycardia, headache, allergic reactions, nausea, vomiting, pallor, central nervous system disturbances and muscle rigidity have been reported with the use of tropicamide. Psychotic reactions, behavioral disturbances, and vasomotor or cardiorespiratory collapse in children have been reported with the use of anticholinergic drugs.
Source: US FDA prescribing information
Interactions
Tropicamide may interfere with the antihypertensive action of carbachol, pilocarpine, or ophthalmic cholinesterase inhibitors.
Source: US FDA prescribing information
Storage
Store at 8°C to 27°C (46°F-80°F). Do not refrigerate or store at high temperatures. Avoid freezing.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
All presentations
3 presentations of Tropicamide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Tropicamide 10 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Tropicamide 5 mg/mL eye dropsOphthalmicGeneric name | — | US FDA | Available on request |
| Mydriacyl 10 mg/mL eye dropsOphthalmic | Alcon Laboratories | US FDA | Available on request |
Brands by market
1 brand names across 1 markets.
United States
Manufacturers
Regulatory status
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 23 February 1960 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions
Conditions linked to Tropicamide in public data. This is not a list of approved uses, see the clinical information.
Questions and answers
Is Tropicamide available for export from India?
Yes, on request. MedsAcross lists 3 presentations of Tropicamide and sources them for licensed hospitals, importers and physicians against valid import documents.
What brand names does Tropicamide have?
The catalogue lists 1 brand names for Tropicamide, including Mydriacyl.
Is Tropicamide approved by the US FDA?
Yes. The US FDA first approved Tropicamide on 23 February 1960, according to Drugs@FDA.
Does Tropicamide need cold chain shipping?
No listed presentation of Tropicamide is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Which ATC class is Tropicamide in?
Tropicamide is classified under ATC code S01FA06 (Tropicamide).
References
- Tropicamide prescribing information (Somerset Therapeutics). U.S. National Library of Medicine, DailyMed. Retrieved 10 April 2026
Request Tropicamide for export supply
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.